Linked Life Data

10690531

Source:http://linkedlifedata.com/resource/pubmed/id/10690531

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2000-3-28
pubmed:abstractText
The levels of cysteine proteinase inhibitors stefin A, stefin B, and cystatin C were determined using ELISAs in sera obtained preoperatively from 345 patients with colorectal cancer and in control sera from 125 healthy blood donors. The levels of stefin A and cystatin C were found to be moderately increased in patient sera (1.4-fold and 1.6-fold, respectively; P < 0.0001), whereas the level of stefin B remained statistically unchanged when compared with controls. The medians were 4.3 ng/ml versus 3.2 ng/ml for stefin A, 1.2 ng/ml versus 1.7 ng/ml for stefin B, and 679 ng/ml versus 425 ng/ml for cystatin C. In patient sera, a weak correlation of cystatin C with age (r = 0.34; P < 0.001) and gender (P = 0.01) was found. Stefin A and cystatin C levels were independent of Dukes' stage, whereas stefin B correlated significantly with Dukes' stage, its level being the highest in stage D (P < 0.007). Stefin B and cystatin C correlated with survival, whereas stefin A was not a significant prognostic factor in this study. Using medians as cutoff values, patients with high levels of stefin B and patients with high levels of cystatin C exhibited a significantly higher risk of death than those with low levels of inhibitors (hazard ratio = 1.6; 95% confidence interval, 1.2-2.2; P = 0.002 for stefin B; hazard ratio = 1.3; 95% confidence interval, 1.0-1.8; P = 0.04 for cystatin C). Our results reveal a correlation between high levels of extracellular cysteine proteinase inhibitors and short survival in patients with colorectal cancer, and the data thus support previous studies suggesting a contributing role of protease inhibitors in the progression of cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
505-11
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:10690531-Adult, pubmed-meshheading:10690531-Aged, pubmed-meshheading:10690531-Aged, 80 and over, pubmed-meshheading:10690531-Analysis of Variance, pubmed-meshheading:10690531-Colorectal Neoplasms, pubmed-meshheading:10690531-Cystatin A, pubmed-meshheading:10690531-Cystatin B, pubmed-meshheading:10690531-Cystatin C, pubmed-meshheading:10690531-Cystatins, pubmed-meshheading:10690531-Cysteine Proteinase Inhibitors, pubmed-meshheading:10690531-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:10690531-Female, pubmed-meshheading:10690531-Follow-Up Studies, pubmed-meshheading:10690531-Humans, pubmed-meshheading:10690531-Male, pubmed-meshheading:10690531-Middle Aged, pubmed-meshheading:10690531-Multivariate Analysis, pubmed-meshheading:10690531-Neoplasm Staging, pubmed-meshheading:10690531-Prognosis, pubmed-meshheading:10690531-Reference Values, pubmed-meshheading:10690531-Risk Factors, pubmed-meshheading:10690531-Time Factors, pubmed-meshheading:10690531-Tumor Markers, Biological
pubmed:year
2000
pubmed:articleTitle
Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis.
pubmed:affiliation
Jozef Stefan Institute, Department of Biochemistry and Molecular Biology, Ljubljana, Slovenia. janko.kos@ijs.si
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't